Objectives-To evaluate the accuracy and safety of repeated ultrasound-guided core needle biopsy (CNB) for hepatic focal lesions and to assess the predictive factors for success of repeated CNB.
U ltrasound (US)-guided core needle biopsy (CNB) is a wellknown and effective method for achieving a pathologic diagnosis of hepatic focal lesions. 1, 2 Core needle biopsy is generally regarded as safe, with low mortality and morbidity and reported accuracy of greater than 90% (93.5%-97.5%). 1, 3, 4 In clinical practice, repeated CNB is performed when the initial pathologic results are inconclusive or unexpected. However, to our knowledge, no study has been focused on the effectiveness of repeated CNB of focal liver lesions. Appelbaum et al 1 evaluated the predictive factors of successful biopsy but were unable to determine any statistically significant predictive factors for the initial CNB. Therefore, the purpose of our study was to evaluate the accuracy and safety of repeated CNB in patients with hepatic focal lesions and to assess the factors predicting repeated CNB success.
Materials and Methods

Study Population
The Review Board of our institution approved this study. Informed consent was waived for this retrospective analysis. From 2009 to 2013, 6413 liver CNBs were performed at our institution. Of these, 3085 CNBs, including both initial and repeated CNBs (48.1%), were performed for focal lesions in the liver. Repeated CNBs were performed in 78 patients because of pathologically inconclusive results on the initial CNB, such as necrotic material or unexpected findings. Five of these patients who had inconclusive results on repeated CNB at the time of radiofrequency ablation of the mass were excluded because additional tissue or follow-up imaging was not available. Five of these patients who had repeated CNB greater than 3 months after the first CNB were excluded because the characteristics of mass could have changed, and the degree of the biopsy difficulty could also have changed during this time. In 1 of those 5 patients, the result of the first biopsy was an organizing abscess, and 8 months after the first biopsy, the lesion had increased in size; there was better tumor conspicuity; and the result of the second biopsy verified adenocarcinoma. In 2 of those 5 patients, the result of the first biopsy was non-neoplastic liver. Nine and 18 months after the first biopsy, the lesions had decreased in size; there was better tumor conspicuity; and the results of the second biopsy showed metastasis. In 2 of those 5 patients, the results of the first biopsy were inactive cirrhosis and moderate portal inflammation, respectively. Three months after the first biopsy, the lesions were more well defined, and the results of the second biopsy were hepatocellular carcinoma and a high-grade dysplastic nodule, respectively. Those masses could progress from cirrhotic liver to hepatocellular carcinoma and a dysplastic nodule. Two patients with non-neoplastic results were excluded because of insufficient follow-up time of less than 1 year.
Finally, 66 patients were included in this study. Of the 66 patients with repeated biopsies, 55 were included in the diagnostic group (true positive and true negative), and 11 were included in the nondiagnostic group (false negative or false positive) compared with the final results. When malignancy was detected on the pathologic biopsy results, including CNB, and the results of other methods, such as endoscopic biopsy and computed tomography (CT)-guided biopsy, were released, it was regarded as the final diagnosis. When a benign lesion or non-neoplastic liver was noted on pathologic examination, if surgery was performed, the surgical pathologic result was defined as the reference standard. If surgery was not performed, follow-up imaging was considered the reference standard. When a mass increased in size or there was metastasis seen on follow-up imaging, the lesion was considered to be malignant (true positive or false negative), and when a mass did not have a substantial interval change for greater than 1 year or regressed without chemotherapy, the lesion was considered to be benign (true negative). A flow diagram describing the recruitment of the study population is shown in Figure 1 .
Ultrasound-Guided Biopsy Technique
Biopsies were performed by 1 of 5 abdominal radiologists who had greater than 5 years of interventional US experience or by a board-certified abdominal Fellow (5 or 6 in each academic year, <than 2 years of clinical experience) under the supervision of a staff radiologist. All repeated CNBs were performed with a US system (Acuson Sequoia 512; Siemens Medical Solutions, Mountain View, CA; of iU22, Philips Healthcare, Bothell, WA) equipped with a 2-5-MHz convex transducer and a semiautomated biopsy gun with an 18-gauge needle (Stericut; TSK Laboratory, Tochigi, Japan). The biopsy was targeted toward the solid portion of the mass, in particular, the periphery of the mass. A biopsy was performed 2 to 4 times, and the biopsy needle was directly advanced into the lesion without the use of a coaxial needle. Onsite cytologic assessment was not available. The adequacy of lesional tissue in the specimen was determined with radiologic confidence on US imaging in that the cutting needle had traversed the mass, and the gross specimen had whitish material if the lesion was a suspicious solid mass. All patients met the coagulation profile: namely, a platelet count of greater than 150 3 10 3 /mm 3 , an international normalized ratio of less than 1.4, and an activated partial thromboplastin time of less than 35 seconds. 5 Patients with coagulopathy were treated before CNB. Informed consent was obtained before each biopsy. Two or 3 needle passes are the standard number for US-guided liver biopsy at our institution. In all patients, we used the freehand technique and did not use an attachable needle guide for the biopsy.
Data Analysis
The pathologic CNB results, agreement with the final diagnosis, and reasons for the repeated biopsy were evaluated by 2 radiologists (H.J.W and J.S.K), who were unaware of the final patient diagnosis and who analyzed the images in consensus. Tumor necrosis (>50% of the mass, necrosis degree of the tumor evaluated by all diagnostic methods, such as magnetic resonance imaging, CT, positron emission tomography/CT, and US), tumor size, number of passes, lesion site (segment), depth, tumor conspicuity (ie, good, clearly visible in any state of respiration; fair, clearly visible in the constant state of respiration; poor, partially visible tumor even in deep inspiration or tumor with poor conspicuity; or impossible, invisible tumor), and complications were also recorded. Complications were classified as minor and major according to the Society for Interventional Radiology guidelines. 6 We could not determine whether to use the subcostal or intercostal biopsy approach because of the retrospective review. 
Statistical Analysis
Results
Of the 3007 initial CNBs, a definitive diagnosis was made in 2819 patients (93.7%). In the remaining 266 patients, a repeated biopsy was performed in 78 (29%). Of the 188 patients without a repeated biopsy, they underwent surgery (n 5 63), follow-up imaging (n 5 52), radiofrequency ablation (n 5 19), biopsy at another site such as a lymph node or pancreas (n 5 18), transarterial chemoembolization (n 5 18), and endoscopic US-guided biopsy (n 5 7). Eleven patients were lost to follow-up. Most of the repeated CNBs were performed at the same site as the initial CNB, except in 3 patients, in whom there were multiple metastases. The overall repeated CNB rate was 2.5% (78 of 3085). No patient underwent a third repeated biopsy within 4 weeks after the first biopsy. Metastasis was the most common reason for a repeated CNB (n 5 21), followed by cholangiocarcinoma (n 5 19) and hepatocellular carcinoma (n 5 11).
The 66 patients who had repeated biopsies included 51 men and 15 women (mean age, 57.9 years; age range, 26-80 years). Of the 66 repeated biopsies included in our study, based on the final pathologic results, 56 were ultimately proven to be malignant, and 10 were benign. However, based on the CNB results, of the 66 repeated biopsies, 11 were false negative (benign or negative on CNB and finally confirmed as malignancy); 45 were true positive; and 10 were true negative. Therefore, the diagnostic accuracy of the repeated biopsy was 83.3% (1) Organizing abscess (1) Cavernous hemangioma (1) Cavernous hemangioma (1) a Case was proven to be nodular hepatic necrosis by surgery. Two cases were diagnosed by endoscopic biopsy, and 3 cases were assumed to be malignancy on follow-up imaging. c Three cases were assumed to be metastasis on follow-up imaging because of the increased size of the mass and newly appearing metastasis. (55 of 66); the sensitivity was 80.4% (45 of 56); and the specificity was 100% (10 of 10).
The indications for repeated CNB were inconclusive pathologic results (n 5 14) and unexpected pathologic results, which were inconsistent with the radiologic or clinical findings (n 5 52). The causes and conclusions of the diagnostic cases (ie, true positive and true negative) and the nondiagnostic cases (ie, false positive and false negative) are summarized in Tables 1 and 2 . Of 11 nondiagnostic cases, 6 patients were assumed to have a malignancy on follow-up imaging due to metastasis in other lesions or an increased size of the mass; 2 patients had a diagnosis by surgery; 2 had a diagnosis by endoscopic biopsy; and 1 had a diagnosis by CT-guided biopsy. Of the 14 patients with inconclusive pathologic results on the initial CNB (diagnostic cases, n 5 12; nondiagnostic cases, n 5 2), 11 cases were due to necrotic material. In the non-diagnostic patient group, cholangiocarcinoma (n 5 5), especially of the periductal infiltrative type (n 5 4), was the most common final diagnosis, followed by hepatocellular carcinoma (n 5 3) and metastasis (n 5 3).
There were no significant differences between the diagnostic and nondiagnostic groups in any of the variables analyzed (ie, size, depth, tumor necrosis [>50% of the mass], lesion site [segment], and number of passes) that could predict a successful repeated CNB. Tumor conspicuity was a significant predictor of repeated CNB success (P < .001). The variables are summarized in Table 3 .
The cumulative repeated biopsy complication rate was 10.6% (7 of 66). Moderate to severe pain requiring analgesics or a visual analog scale score of greater than 5 was seen in 6 patients, and 1 patient developed fever.
Discussion
In this study, the overall diagnostic accuracy of the initial CNB was 93.7%. This rate was similar to that seen in previous studies (93.3%-98.6%). [1] [2] [3] The diagnostic accuracy of the repeated CNB (83.3%) was lower than that of the initial CNB, possibly because most repeated CNBs are more difficult to perform than the initial CNBs. The cumulative complication rate of repeated CNB in our study was 10.6%, which was similar to and at the upper limit as values in previous reports regarding rates for initial CNB of 0% to 11%. 1, [7] [8] [9] This result might have been due to the cumulative complications of initial and repeated CNBs. No patients had major complications or were hospitalized as a complication of the biopsy.
Metastasis was the most common requirement for repeated CNB, possibly because metastasis is one of the most common focal hepatic lesions, and clinicians prefer pathologic confirmation when liver metastasis is seen. In addition, when the typical images of intrahepatic cholangiocarcinoma and hepatocellular carcinoma are seen, clinicians usually treat hepatic focal lesions using other methods, such as surgery, radiofrequency ablation, and transarterial chemoembolization. 10 In the 14 patients with inconclusive pathologic results from repeated CNB, the presence of necrotic material was the most common reason for the repeated CNB (11 of 14 [78.6%]). In general, efforts should be made to biopsy the peripheral, non-necrotic portion of such lesions. In addition, targeting of enhancing lesions on CT, magnetic resonance imaging, or contrastenhanced US may improve the biopsy yield. In our study, the most common cause of unexpected pathologic results was mistargeted biopsy (96.2% [50 of 52]; 41 patients in the diagnostic group and 9 patients in the nondiagnostic group). Of the 11 nondiagnostic patients, 4 had periductal, infiltrative-type ductal cholangiocarcinoma with no visible hepatic lesions or small hepatic lesions of less than 1 cm. Therefore, when patients with Data are presented as mean 6 SD where applicable. Tumor necrosis and tumor conspicuity were defined as described in "Materials and Methods."
nondiagnostic results on the initial CNB are highly suspected of having periductal, infiltrative-type cholangiocarcinoma with no visible hepatic lesions or small hepatic lesions of less than 1 cm, it is preferable to use a different method to confirm hepatic focal lesions rather than repeated CNB. The tumor size, depth, tumor necrosis (<50% of the mass), lesion site (segment), and number of passes were not significant predictive factors for the success of repeated CNB. This result is mostly consistent with that of an initial CNB study by Appelbaum et al. 1 A study of US-and CT-guided CNB of small focal hepatic lesions reported that the location could predict the biopsy success, 3 with tumors located in the caudate lobe predicting biopsy failure. In our study, the lesion size was larger and the lesion depth was more shallow and without greater statistical significance in the diagnostic group than in the nondiagnostic group. The lesion site (segment) was also not a significant factor predicting repeated CNB success. The lesion site classified simply by segment might be insufficient to diagnose "access difficulty." The number of passes was slightly and insignificantly higher in the nondiagnostic group than in the diagnostic group. Because the mean number of passes was less than 3 in both groups, 3 passes might be sufficient to diagnose hepatic focal lesions. This finding is similar to that of a previous study. 1, 10 Tumor conspicuity significantly predicted biopsy success. Therefore, it is important to consider tumor conspicuity to determine the necessity of a repeated CNB.
Our study had several limitations. First, it was a retrospective study in which we retrospectively evaluated previous US images at the time of the repeated CNB. Lesions deemed too poorly visualized or with major complications seen on the initial CNB may not have been chosen for rebiopsy, which could have led to a potential selection bias in this retrospective analysis. Second, the number of nondiagnostic rebiopsies was relatively small (n 5 11), which could have made analysis of the statistical significance difficult. Third, because of the design of our study that positive biopsy results were considered "final" (in other words, a biopsy positive for malignancy could not be benign), there were no falsepositives results in this study.
In conclusion, repeated CNB is an accurate and safe procedure for the histologic diagnosis of hepatic focal lesions. The most common reason for repeated CNB was a mistargeted biopsy, followed by necrotic material. High tumor conspicuity was significantly correlated with the success of repeated biopsy procedures.
